Pipemidic acid is a new chemotherapeutic drug, developed in Japan. The minimal inhibitory concentration of pipemidic acid for 47 of the 50 strains of E. coli clinically isolated ranged 0.78-4. 56 μg/ml.
The minimal inhibitory concentration of this drug for 42 of the 50 strains of Klebsiella clinically isolated ranged 1.56-3.13 μg/ml.
The minimal inhibitory concentration for 34 of the 50 strains of Pseudomonas aeruginosa was 12. 5μg/ml.
The serum concentrations and the urinary excretions of pipemidic acid after oral administration were examined in 3 healthy volunteers in the fasting state. The peak of serum concentrations given 500 mg of pipemidic acid was 3. 5 to 4. 5 μg/mi at 1 hour after the administration, and the serum concentrations at 6 hours after the administration were undetectable.
The peak of serum concentrations given 1, 000 mg of pipemidic acid was 4. 1 to 5.7μg/ml at 1 or 2 hours after administration, and the serum concentrations at 6 hours after administration were undetectable.
The average urinary recoveries within 6 hours after the administration of 500 mg and 1, 000 mg of pipemidic acid were 54.7% and 46.7% respectively.
On the therapeutic efficacy of this drug to 8 cases of bacterial infections, clinical responses were good in 4 of 5 cases of urinary tract infections and in 1 of 3 cases of biliary infections.
There were no side effects of this drug clinically and in clinical laboratory tests.
